Sonoma Pharma Reports 37% Revenue Growth to $19.5M, Cash Runway Tightens Amid Losses
SNOA sits 29% above its 52-week low of $0.85.
Summary
Sonoma Pharmaceuticals reported fiscal 2026 revenue of $19.5 million, a 37% increase year-over-year, with diluted EPS improving to a loss of $(1.89). This earnings report, summarized from the 10-K filed today, confirms the company's continued net loss and highlights a tightened cash runway. Management expects to need additional equity or debt financing to fund near-term operations, following a highly dilutive $4 million public offering in April. Despite revenue growth, the ongoing losses and need for further capital indicate significant financial challenges for this micro-cap company.
At the time of this announcement, SNOA was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.85 to $6.92. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.